Sionna Therapeutics Sells 33,356 Shares for $1.49M on Dec 24, 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3d ago
0mins
Source: NASDAQ.COM
- Stock Sale: On December 24, 2025, Sionna Therapeutics sold 33,356 shares for $1.49 million through OrbiMed Private Investments VIII, LP, reducing its indirect ownership to 3,561,655 shares, demonstrating the company's liquidity management capabilities in the market.
- Market Response: The number of shares sold matched the median for recent disposals, indicating that the company can maintain a stable shareholder structure even after a series of large transactions, thereby enhancing market confidence.
- Financial Position: Sionna Therapeutics raised approximately $191 million in its initial public offering last February, with funds allocated to advance its innovative treatments for cystic fibrosis, showcasing the company's potential in the biopharmaceutical sector.
- R&D Progress: The company announced positive phase 1 results for its lead candidates SION-719 and SION-451 in healthy volunteers in June, with top-line results from the phase 2 trial expected around mid-next year, further boosting its competitiveness in the rare disease market.
Analyst Views on SION
Wall Street analysts forecast SION stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SION is 40.00 USD with a low forecast of 24.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 40.850
Low
24.00
Averages
40.00
High
46.00
Current: 40.850
Low
24.00
Averages
40.00
High
46.00
About SION
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on researching and developing novel medicines for cystic fibrosis. It is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). It is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. It is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
